Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, Davis
M.D. Anderson Cancer Center
Replimune Inc.
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AgonOx, Inc.
Novartis
Inhibrx Biosciences, Inc
University Health Network, Toronto
AstraZeneca
Milton S. Hershey Medical Center
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
Checkpoint Therapeutics, Inc.
Dana-Farber Cancer Institute
iTeos Therapeutics
R-Pharm
AO GENERIUM